Clinical Trials Logo

Clinical Trial Summary

The main objective is to evaluate the efficacy of sensor augmented pump (SAP) therapy with MiniMed 640G with SmartGuard activation in preventing hypoglycemia events in comparison sensor augmented pump (SAP) therapy with Minimed 640G without SmartGuard activation in type 1 diabetic adults with an increased risk of hypoglycemia.

The study should show:

- A reduction in the number of severe hypoglycemia, fewer hypoglycemic events and a reduction in the time spent in hypoglycemia six months in any group compared to Baseline.

- A complete prevention of severe and not severe hypoglycemia in the pump group Minimed 640G + Enlite sensor with SmartGuard activation


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02657213
Study type Interventional
Source University Hospital, Grenoble
Contact
Status Completed
Phase N/A
Start date February 2016
Completion date June 2017

See also
  Status Clinical Trial Phase
Completed NCT02601729 - Reimbursement Study of Continuous Glucose Monitoring in Belgium
Completed NCT01805414 - Breakfast Nutrition and Inpatient Glycemia N/A
Terminated NCT00700622 - Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks Phase 3
Completed NCT00308737 - Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes Phase 3
Terminated NCT01350102 - The Relationship of Hemoglobin A1c and Diabetic Wound Healing Phase 4
Withdrawn NCT03494010 - Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant
Completed NCT02214719 - Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care N/A